Esophageal cancer screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (One intermediate revision by one other user not shown) | |||
| Line 3: | Line 3: | ||
==Overview== | ==Overview== | ||
Screening for esophageal cancer has not been established. Screening may be effective in reducing the incidence of esophageal adenocarcinoma, especially in Barrett's esophagus, but is left at the physician's discretion. | Screening for esophageal cancer has not been established. Screening may be effective in reducing the [[incidence]] of esophageal adenocarcinoma, especially in Barrett's esophagus, but is left at the physician's discretion. | ||
==Screening== | ==Screening== | ||
| Line 9: | Line 9: | ||
===Adenocarcinoma screening=== | ===Adenocarcinoma screening=== | ||
*The predominant type of esophageal cancer in the United States is [[adenocarcinoma]].<ref name="pmid26185366">{{cite journal |vauthors=Domper Arnal MJ, Ferrández Arenas Á, Lanas Arbeloa Á |title=Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries |journal=World J. Gastroenterol. |volume=21 |issue=26 |pages=7933–43 |year=2015 |pmid=26185366 |pmc=4499337 |doi=10.3748/wjg.v21.i26.7933 |url=}}</ref> | *The predominant type of esophageal cancer in the United States is [[adenocarcinoma]].<ref name="pmid26185366">{{cite journal |vauthors=Domper Arnal MJ, Ferrández Arenas Á, Lanas Arbeloa Á |title=Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries |journal=World J. Gastroenterol. |volume=21 |issue=26 |pages=7933–43 |year=2015 |pmid=26185366 |pmc=4499337 |doi=10.3748/wjg.v21.i26.7933 |url=}}</ref> | ||
*Since there is a lack of data that records esophageal adenocarcinoma mortality rates, screening is not indicated and is left at the physician's discretion. | *Since there is a lack of data that records esophageal [[adenocarcinoma]] mortality rates, screening is not indicated and is left at the physician's discretion. | ||
*Patients diagnosed with Barrett's esophagus have a higher risk for esophageal adenocarcinoma. | *Patients diagnosed with [[Barrett's esophagus]] have a higher risk for esophageal [[adenocarcinoma]]. | ||
*Screening is therefore recommended for those diagnosed by endoscopy and biopsy for Barrett's esophagus. | *Screening is therefore recommended for those diagnosed by [[endoscopy]] and [[biopsy]] for [[Barrett's esophagus]]. | ||
*Early screening can detect dysplasias and treatment can be implemented to prevent the incidence of esophageal cancer. | *Early screening can detect [[Dysplasia|dysplasias]] and treatment can be implemented to prevent the incidence of esophageal cancer. | ||
*It should also be noted that those who present with [[adenocarcinoma]] demonstrate no prior [[Barrett's esophagus]] in 80 - 90% of the time. | *It should also be noted that those who present with [[adenocarcinoma]] demonstrate no prior [[Barrett's esophagus]] in 80 - 90% of the time. | ||
===Squamous cell carcinoma screening=== | ===Squamous cell carcinoma screening=== | ||
*Screening for squamous cell carcinoma is discouraged in the US because esophageal squamous cell carcinoma carries a very low incidence.<ref name="pmid18341497">{{cite journal |vauthors=Wang KK, Sampliner RE |title=Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus |journal=Am. J. Gastroenterol. |volume=103 |issue=3 |pages=788–97 |year=2008 |pmid=18341497 |doi=10.1111/j.1572-0241.2008.01835.x |url=}}</ref> | *Screening for [[squamous cell carcinoma]] is discouraged in the US because esophageal [[squamous cell carcinoma]] carries a very low incidence.<ref name="pmid18341497">{{cite journal |vauthors=Wang KK, Sampliner RE |title=Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus |journal=Am. J. Gastroenterol. |volume=103 |issue=3 |pages=788–97 |year=2008 |pmid=18341497 |doi=10.1111/j.1572-0241.2008.01835.x |url=}}</ref> | ||
*[[Squamous cell carcinoma]] of the esophagus is more prevalent in underdeveloped countries. | *[[Squamous cell carcinoma]] of the esophagus is more prevalent in underdeveloped countries. | ||
*Screening programs are not yet established worldwide.<ref name="pmid3219974">{{cite journal |vauthors=Lin PZ, Zhang JS, Cao SG, Rong ZP, Gao RQ, Han R, Shu SP |title=[Secondary prevention of esophageal cancer--intervention on precancerous lesions of the esophagus] |language=Chinese |journal=Zhonghua Zhong Liu Za Zhi |volume=10 |issue=3 |pages=161–6 |year=1988 |pmid=3219974 |doi= |url=}}</ref> | *Screening programs are not yet established worldwide.<ref name="pmid3219974">{{cite journal |vauthors=Lin PZ, Zhang JS, Cao SG, Rong ZP, Gao RQ, Han R, Shu SP |title=[Secondary prevention of esophageal cancer--intervention on precancerous lesions of the esophagus] |language=Chinese |journal=Zhonghua Zhong Liu Za Zhi |volume=10 |issue=3 |pages=161–6 |year=1988 |pmid=3219974 |doi= |url=}}</ref> | ||
**A screening program in a high risk population was established in Hishun village, China. | **A screening program in a high risk population was established in Hishun village, China. | ||
**Those with mild to moderate [[dysplasia]] were examined via endoscopy every 3 years, whilst those with severe [[dysplasia]] were screened once per year. | **Those with mild to moderate [[dysplasia]] were examined via endoscopy every 3 years, whilst those with severe [[dysplasia]] were screened once per year. | ||
**All the patients were concomitantly treated with monoclonal antibodies for the next three years. | **All the patients were concomitantly treated with [[monoclonal antibodies]] for the next three years. | ||
**At the end of three year monoclonal antibody trial, the incidence rate of esophageal [[squamous cell carcinoma]] had decreased by 57% in comparison to previous incidence rates. | **At the end of three year [[Monoclonal antibodies|monoclonal antibody]] trial, the incidence rate of esophageal [[squamous cell carcinoma]] had decreased by 57% in comparison to previous incidence rates. | ||
**These results demonstrated that screening for dysplastic changes in the esophagus is effective in the prevention of esophageal squamous cell carcinoma. | **These results demonstrated that screening for [[Dysplasia|dysplastic]] changes in the esophagus is effective in the prevention of esophageal [[squamous cell carcinoma]]. | ||
==References== | ==References== | ||
Latest revision as of 16:04, 5 January 2018
|
Esophageal cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Esophageal cancer screening On the Web |
|
American Roentgen Ray Society Images of Esophageal cancer screening |
|
Risk calculators and risk factors for Esophageal cancer screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Hadeel Maksoud M.D.[2]
Overview
Screening for esophageal cancer has not been established. Screening may be effective in reducing the incidence of esophageal adenocarcinoma, especially in Barrett's esophagus, but is left at the physician's discretion.
Screening
Adenocarcinoma screening
- The predominant type of esophageal cancer in the United States is adenocarcinoma.[1]
- Since there is a lack of data that records esophageal adenocarcinoma mortality rates, screening is not indicated and is left at the physician's discretion.
- Patients diagnosed with Barrett's esophagus have a higher risk for esophageal adenocarcinoma.
- Screening is therefore recommended for those diagnosed by endoscopy and biopsy for Barrett's esophagus.
- Early screening can detect dysplasias and treatment can be implemented to prevent the incidence of esophageal cancer.
- It should also be noted that those who present with adenocarcinoma demonstrate no prior Barrett's esophagus in 80 - 90% of the time.
Squamous cell carcinoma screening
- Screening for squamous cell carcinoma is discouraged in the US because esophageal squamous cell carcinoma carries a very low incidence.[2]
- Squamous cell carcinoma of the esophagus is more prevalent in underdeveloped countries.
- Screening programs are not yet established worldwide.[3]
- A screening program in a high risk population was established in Hishun village, China.
- Those with mild to moderate dysplasia were examined via endoscopy every 3 years, whilst those with severe dysplasia were screened once per year.
- All the patients were concomitantly treated with monoclonal antibodies for the next three years.
- At the end of three year monoclonal antibody trial, the incidence rate of esophageal squamous cell carcinoma had decreased by 57% in comparison to previous incidence rates.
- These results demonstrated that screening for dysplastic changes in the esophagus is effective in the prevention of esophageal squamous cell carcinoma.
References
- ↑ Domper Arnal MJ, Ferrández Arenas Á, Lanas Arbeloa Á (2015). "Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries". World J. Gastroenterol. 21 (26): 7933–43. doi:10.3748/wjg.v21.i26.7933. PMC 4499337. PMID 26185366.
- ↑ Wang KK, Sampliner RE (2008). "Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus". Am. J. Gastroenterol. 103 (3): 788–97. doi:10.1111/j.1572-0241.2008.01835.x. PMID 18341497.
- ↑ Lin PZ, Zhang JS, Cao SG, Rong ZP, Gao RQ, Han R, Shu SP (1988). "[Secondary prevention of esophageal cancer--intervention on precancerous lesions of the esophagus]". Zhonghua Zhong Liu Za Zhi (in Chinese). 10 (3): 161–6. PMID 3219974.